메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Rafa Laboratories Awarded up to $186 Million by BARDA to Deve…

JERUSALEM, Nov. 19, 2025 -- Rafa Laboratories, a global leader in Chemical, Biological, Radiological, and Nuclear hazards medical countermeasures and Biodefense, today announced it has been awarded with a landmark development contract by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services (HHS), for the advanced development of a novel intramuscular (IM) formulation of tranexamic acid (TXA)—a potentially life-saving therapy for uncontrolled bleeding. The contract
- 김갑성 기자
- 2025-11-19 13:01
Older Singaporeans Support Healthier SG, but Lifestyle Habits…

New SMU research reveals critical gaps in preventive health, lifestyle habits, and continuity of care as Singapore transitions into a super-aged society. Despite strong pro-health policies, everyday adoption - especially among older adults - remains limited. Bridging this gap requires environmental nudges that make healthy choices easier, more intuitive, and part of daily life. The upcoming symposium will explore these challenges and spotlight opportunities to strengthen pro-health behaviours. SINGAPORE, Nov. 19, 2025 -- A new study by the Singapore Management Uni
- 김갑성 기자
- 2025-11-19 12:30
Lynk Pharmaceuticals Announces Key Phase II Clinical Res…

HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin restricted, soft pan-JAK inhibitor, for the treatment of atopic dermatitis (AD). This randomized, double-blind, vehicle-controlled Phase II study evaluated the efficacy and safety of topical LNK01004 ointment (0.3% and 1.0%) in adult patients with moderate-to-severe AD. A total of 75 patients were enroll
- 김갑성 기자
- 2025-11-19 08:00
Rafa Laboratories Awarded up to $186 Million by BARDA to Deve…

JERUSALEM, Nov. 19, 2025 -- Rafa Laboratories, a global leader in Chemical, Biological, Radiological, and Nuclear hazards medical countermeasures and Biodefense, today announced it has been awarded with a landmark development contract by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services (HHS), for the advanced development of a novel intramuscular (IM) formulation of tranexamic acid (TXA)—a potentially life-saving therapy for uncontrolled bleeding. The contract
- 김갑성 기자
- 2025-11-19 06:00
Rafa Laboratories、院前医療向け救命筋肉内TXA注射剤開発でBARDAから最大…

エルサレム, 2025年11月19日 -- 化学、生物、放射線、核危険物質に対する医療対策および生物防衛分野の世界的リーダーであるRafa Laboratoriesは本日、U.S. Department of Health and Human Services（HHS）、Administration for Strategic Preparedness and Response傘下のBiomedical Advanced Research and Development Authority（BARDA）より、トランスエキシメート酸（TXA）の新規筋肉内（IM）製剤の先進開発に関する画期的な開発契約を獲得したことを発表しました。これは、制御不能な出血に対して潜在的に命を救う治療法になり得るものです。本契約の総額はオプション期間を含め最大1億8,600万ドルに達します。 RafaがBARDAと締結した2件目の主要契約となるこの重要な提携は、世界的に緊急のニーズに対応するものです。すなわち、救急現場というきわめて重要な環境下で、迅速に展開可能かつ投与容易な出血治療法を提供することです。命を救うための決定的な時間枠への対応事故、大量の傷病者が発生する事件、戦場を問わず、外傷後の予防可能な死因の首位は制御不能な出血です。医療従事者は、短時間で多
- 김갑성 기자
- 2025-11-19 06:00
라파 연구소, BARDA로부터 최대 1억 8600만 달러 지원받아… 병원 전 단계용 생명구조 근육…

예루살렘, 2025년 11월 19일 -- 라파 연구소(Rafa Laboratories)가 19일 미국 보건복지부(Department of Health and Human Services•HHS) 산하 전략적 대비•대응국(Administration for Strategic Preparedness and Response) 일원인 생물의학 첨단연구개발청(Biomedical Advanced Research and Development Authority•BARDA)으로부터 중대한 개발 계약을 수주했다고 발표했다. 이번 계약은 화학•생물•방사선•핵(CBRN) 위험 의료 대응 및 생물방어 분야의 글로벌 선도기업 라파가 BARDA와 체결한 두 번째 주요 계약으로, 모든 옵션 기간을 포함해 최대 1억 8600만 달러 규모다. 이와 같은 중대 협력은 전 세계가 직면한 긴급한 요구, 즉, 결정적인 병원 전 단계에서 신속하게 투여할 수 있으면서 사용이 용이한 출혈 치료에 대응할 수 있게 됐다는 점에서 중대한 의미를 가진다. 생명을 구하는 결정적 '골든타임' 내 대응 사고, 대량 사상자 발생 사건, 전장 중 어디서 발생하든 간에 통제되지 않은
- 김갑성 기자
- 2025-11-19 06:00
Kazia Therapeutics Achieves Initial iCR (Immune-Complete R…

SYDNEY, Nov. 19, 2025 -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized single-patient expanded access protocol combining paxalisib with pembrolizumab (Keytruda®) and standard chemotherapy has achieved an initial immune-complete response (iCR) per iRECIST criteria. This outcome suggests a profound radiologic response in a highly aggressive metastatic cancer subtype. This development builds upon Kazia's October 2, 2025 announceme
- 김갑성 기자
- 2025-11-19 05:15
아지노모토 바이오파마 서비스, 2025 월드 ADC 어워드에서 AJICAP® 기술로 '2024년 최우…

이번 수상으로 아지노모토 바이오파마 서비스의 혁신과 과학적 우수성이 차세대 항체-약물 접합체 기술 발전에 이바지하고 있음이 입증되었다 도쿄, 2025년 11월 18일 -- 생물약제 위탁 개발 및 제조 서비스 분야를 선도하는 아지노모토 바이오파마 서비스(Ajinomoto Bio-Pharma Services, 이하 '아지 바이오파마')가 오늘 AJICAP® 링커 기술을 다룬 자사의 혁신적인 연구 논문이 제12회 월드 ADC 어워드(World ADC Awards)에서 '2024년 최우수 ADC 전임상 논문(Best ADC Preclinical Publication 2024)' 수상작으로 선정되었다고 전했다. 의약화학 저널(Journal of Medicinal Chemistry)에 게재된 수상 논문 '외부 절단 방식 링커: 항체-약물 접합체의 안정성과 치료 효과 개선(Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody–Drug Conjugates)에는 아지 바이오파마의 AJICAP® 위치 특이적 접합 및 링커 기술에 대한
- 김갑성 기자
- 2025-11-18 21:31
Kangpu to Present Latest Study Results of epaldeudomide…

HEFEI, China, Nov. 18, 2025 -- Kangpu Biopharmaceuticals announced today that the company will deliver a poster presentation to highlight the Phase I clinical trial results of epaldeudomide (KPG-818) for the treatment of hematological malignancies at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida, USA. Poster Title: KPG-818, a Novel Cereblon (CRBN) Modulator, in Patients with Hematological Malignancies: Results of a Phase I, Open-Label, Multiple Ascending Dose Study Poster Number: 5809
- 김갑성 기자
- 2025-11-18 21:00
HKUST Receives Government's Approval to Establish a New Me…

[ 메디채널 김갑성 기자 ] Dedicated to Nurturing a New Generation of DoctorsSupporting Hong Kong Become a Hub for Medical Innovation HONG KONG, Nov. 18, 2025 -- The establishment of Hong Kong's third medical school at The Hong Kong University of Science and Technology (HKUST) was approved today by the Hong Kong SAR Government (the Government). This landmark decision underscores the visionary leadership of the Government in fortifying Hong Kong's medical system. The University expresses its deepest gratitude to the Hong Kong SAR Government for its trust and to the dedicated Task Group on
- 김갑성 기자
- 2025-11-18 19:57

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-11-19_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 19일 15시 20분